m344

M344 (Histone Deacetylase Inhibitor III) is a potent HDAC inhibitor with IC50 of 100 nM and able to induce cell differentiation.

BPAM344 is a potent positive allosteric modulator (PAM) of the KAR subunits GluK1b, GluK2a, and GluK3a.

YM-344031 is an orally administered antagonist targeting CCR3. It effectively inhibits the binding of Eotaxin-1 and RANTES to CCR3, with IC50 values of 3.0 and 16.3 nM, respectively. YM-344031 also suppresses ligand-induced increases in intracellular Ca [2+] levels and chemotaxis, alters eosinophil morphology induced by eotaxin-1 in macaque blood, and prevents allergic skin reactions in a mouse allergy model.

Imatinib (Standard) is a reference standard for research and analysis in studies involving Imatinib. Imatinib (STI571) is a multi-targeted receptor tyrosine kinase inhibitor that selectively inhibits the kinase activities of BCR/ABL, v-Abl, PDGFR, and c-kit with oral activity. Imatinib has antitumor activity for the treatment of chronic granulocytic leukemia.

Clozapine (Standard) is a reference standard for research and analysis in studies involving Clozapine. Clozapine (HF 1854) is a tricylic dibenzodiazepine, classified as an atypical antipsychotic agent. It binds several types of central nervous system receptors, and displays a unique pharmacological profile. Clozapine is a serotonin antagonist, with strong binding to 5-HT 2A/2C receptor subtype. It also displays strong affinity to several dopaminergic receptors, but shows only weak antagonism at the dopamine D2 receptor, a receptor commonly thought to modulate neuroleptic activity.

Pemetrexed (Standard) is a reference standard for research and analysis in studies involving Pemetrexed. Pemetrexed (LY-231514 Disodium Hydrate), a guanine-derived antineoplastic agent, binds to and inhibits the enzyme thymidylate synthase (TS).

Mycophenolate Mofetil (Standard) is a reference standard for research and analysis in studies involving Mycophenolate Mofetil. Mycophenolate Mofetil (TM-MMF), an immunosuppressive agent, is the 2-morpholinoethyl ester of mycophenolic acid (MPA), and an inhibitor of inosine monophosphate dehydrogenase (IMPDH).

Rifabutin (Standard) is a reference standard for research and analysis in studies involving Rifabutin. Rifabutin (LM-427) inhibits bacterial DNA-dependent RNA polymerase, thereby suppressing the initiation of RNA formation and leading to inhibition of RNA synthesis and transcription. Rifabutin is a semisynthetic ansamycin antibiotic with potent antimycobacterial properties.

Trazodone hydrochloride (Standard) is a reference standard for research and analysis in studies involving Trazodone hydrochloride. Trazodone hydrochloride (Trazodone HCl) is a serotonin uptake inhibitor that is used as an antidepressive agent. It has been shown to be effective in patients with major depressive disorders and other subsets of depressive disorders. It is generally more useful in depressive disorders associated with insomnia and anxiety.

Gemcitabine (Standard) is a reference standard for research and analysis in studies involving Gemcitabine. Gemcitabine (LY188011) is a synthetic cytosine nucleoside derivative and an inhibitor of DNA synthesis. Gemcitabine has antitumor and antimetabolic activities. Gemcitabine induces autophagy and apoptosis.

Sunitinib (Standard) is a reference standard for research and analysis in studies involving Sunitinib. Sunitinib (SU 11248) is a multi-targeted receptor tyrosine kinase (RTK) inhibitor that inhibits VEGFR2 and PDGFRβ (IC50=80/2 nM). Sunitinib has antitumor activity and can be used for the treatment of kidney cancer and gastrointestinal tumors.

Itraconazole (Standard) is a reference standard for research and analysis in studies involving Itraconazole. Itraconazole (R51211) belongs to the triazole group of natural products and is an antifungal agent with oral activity. Itraconazole is a Hedgehog signaling pathway antagonist, an oxysterol-binding protein (OSBP) inhibitor, and an inhibitor of cytochrome P-450-dependent enzymes.

Dasatinib (Standard) is a reference standard for research and analysis in studies involving Dasatinib. Dasatinib (BMS-354825) is a tyrosine kinase inhibitor that inhibits Src and Bcr-Abl (Ki=16/30 pM) and is orally active and ATP-competitive. Dasatinib has antitumor activity and is used in the treatment of leukemia and lymphoma.